Aethlon Medical Inc. (OTCBB: AEMD), developer of innovative medical devices that address multiple unmet medical needs in cancer, infectious disease and other life-threatening conditions, announced last month that the U.S. FDA approved an Investigational Drug Application as a precursor to human feasibility studies of the Aethlon Hemopurifier® in the U.S. If approved, the technology could generate significant revenues across multiple indications.
In addition to its progress in the U.S., the company just announced that the European Patent Office granted its patent number 1624784, entitled “method of removal of viruses from blood by lectin affinity hemodialysis”. The patent complements its existing U.S. patents and potentially sets the stage for a European rollout in the future. Meanwhile, the unique therapy has also previously been offered in India with excellent results across the board.
The Aethlon Hemopurifier® has numerous market applications, ranging from the treatment of HCV-infected ESRD patients to exosome-prone cancer patients. Working with existing standard-of-care drug treatments, such as peginterferon and ribavirin from Roche Holding AG (OTC: RHHBY), it involves far less toxicity than more aggressive drug therapies like Achillion Pharmaceuticals’ (NASDAQ: ACHN) sovaprevir, potentially making it a preferred treatment option.
Click here to get updates on Aethlon Medical: http://www.emerginggrowthcorp.com/emailassets/aemd/aemd_landing.php
Read the press release announcing the new patent below:
Aethlon Medical, Inc. (AEMD), announced today that the European Patent Office has provided the Company with a Decision To Grant A Patent entitled "METHOD OF REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS". The European Patent will be assigned Patent No. 1624784 and has been referenced in European Patent Office Bulletin No. 13/29. The registration of the patent expands the protection of the Aethlon Hemopurifier® and includes designations in the United Kingdom, Germany, Ireland, Italy, France, and Belgium. The Hemopurifier® is a first-in-class medical device that targets the rapid elimination infectious viral pathogens from blood.
Previously, the United States Patent and Trademark Office (USPTO) issued Patent No. 7,226,429 to Aethlon Medical on June 5, 2007. Patent No. 7,226,429 was also entitled: "METHOD OF REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS". On October 16, 2012, the USPTO issued Aethlon Patent No. 8,288,172, which was entitled: "EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES". Patent No. 8,288,172 protects the use of the Aethlon Hemopurifier® as a method to remove immunosuppressive exosomes from blood.
Last month, Aethlon disclosed that the United States Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. Under the feasibility study protocol, Aethlon will enroll ten end stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and potentially other disease conditions.
Specific to the treatment of HCV, the Hemopurifier is uniquely positioned as an adjuvant to be incorporated with either interferon-based standard of care (SOC) or emerging all-antiviral drug regimens without adding drug toxicity. In addition to augmenting the early viral kinetic response to SOC, the Hemopurifier is a candidate solution for viral rebound patients who traditionally are forced to discontinue therapy at the point HCV establishes resistance to drug regimens. Additionally, the Hemopurifier addresses the large population of HCV-infected ESRD patients for which SOC and emerging all-antiviral strategies may be contraindicated or not yet cleared. According to the World Health Organization (WHO), HCV is a blood-borne pathogen that affects upwards of 170 million persons, or 2-3% of the world's population. It is a leading cause of cirrhosis and liver transplantation...
Click here to read the full release: http://aethlonmedical.investorroom.com/2013-07-25-Aethlon-Medical-Announces-European-Patent-to-Remove-Viruses-From-Blood
About Emerging Growth LLC
EGC is a marketing and consulting firm that specializes in creating
ongoing communications strategies for public and private companies.
Disclosure
Except for the historical information presented herein, matters
discussed in this release contain forward-looking statements that are
subject to certain risks and uncertainties that could cause actual
results to differ materially from any future results, performance or
achievements expressed or implied by such statements. Emerging Growth
LLC is not registered with any financial or securities regulatory
authority, and does not provide nor claims to provide investment advice
or recommendations to readers of this release. For making specific
investment decisions, readers should seek their own advice. For full
disclosure please visit: http://secfilings.com/Disclaimer.aspx